Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19F MRI of Ventilation in CF Exacerbation
NCT03497117Phase 1Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2015
- Primary completion
- Sep 2019
- Modality
- GAS (Genetic analysis systems)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren in cystic fibrosis (CF), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Whole lung ventilation defect volume at 1 day. Started Aug 2015; status: terminated.
02
Drugs
perflutren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03497117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497117.